ATHX Stock Overview
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.03|
|52 Week High||US$3.03|
|52 Week Low||US$0.92|
|1 Month Change||-10.44%|
|3 Month Change||-35.22%|
|1 Year Change||-45.79%|
|3 Year Change||-46.35%|
|5 Year Change||-33.97%|
|Change since IPO||-80.38%|
Recent News & Updates
Athersys: COVID-ARDS Is The Company's Most Important Target
I covered Athersys' ischemic stroke trial earlier. The stock has fallen as a result of issues with this trial. However, Covid-induced ARDS is its most important indication, where it has market-leading positive data.
Athersys Shares Are Ready To Rumble Following Period Of Turmoil
Positive ARDS Results in Japan should lead to approval and revenues. Enrollment complete in 220 patient stroke study in Japan. Japan's progressive regenerative medicine approval regulations bode well for success. Athersys shares have not reflected the upside of recent developments.
|ATHX||US Biotechs||US Market|
Return vs Industry: ATHX underperformed the US Biotechs industry which returned 5.3% over the past year.
Return vs Market: ATHX underperformed the US Market which returned 21.3% over the past year.
|ATHX Average Weekly Movement||9.0%|
|Biotechs Industry Average Movement||8.6%|
|Market Average Movement||5.9%|
|10% most volatile stocks in US Market||15.1%|
|10% least volatile stocks in US Market||2.2%|
Stable Share Price: ATHX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ATHX's weekly volatility (9%) has been stable over the past year.
About the Company
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers.
Athersys Fundamentals Summary
|ATHX fundamental statistics|
Is ATHX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ATHX income statement (TTM)|
|Cost of Revenue||US$71.02m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.37|
|Net Profit Margin||-1,442.59%|
How did ATHX perform over the long term?See historical performance and comparison
Is Athersys undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ATHX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ATHX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ATHX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ATHX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATHX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATHX is overvalued based on its PB Ratio (8.3x) compared to the US Biotechs industry average (2.9x).
How is Athersys forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATHX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ATHX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ATHX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ATHX's revenue (70.7% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: ATHX's revenue (70.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ATHX's Return on Equity is forecast to be high in 3 years time
How has Athersys performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATHX is currently unprofitable.
Growing Profit Margin: ATHX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ATHX is unprofitable, and losses have increased over the past 5 years at a rate of 34.9% per year.
Accelerating Growth: Unable to compare ATHX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATHX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: ATHX has a negative Return on Equity (-297.99%), as it is currently unprofitable.
How is Athersys's financial position?
Financial Position Analysis
Short Term Liabilities: ATHX's short term assets ($58.1M) exceed its short term liabilities ($27.7M).
Long Term Liabilities: ATHX's short term assets ($58.1M) exceed its long term liabilities ($15.1M).
Debt to Equity History and Analysis
Debt Level: ATHX is debt free.
Reducing Debt: ATHX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATHX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ATHX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32.3% each year
What is Athersys's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ATHX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ATHX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ATHX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATHX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATHX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
BJ Lehmann (55 yo)
Mr. William Lehmann, also known as B.J., Jr., J.D., M.B.A, has been the President and Chief Operating Officer at Athersys, Inc., since June 2006 and also serves as its Interim Chief Executive Officer since...
CEO Compensation Analysis
Compensation vs Market: BJ's total compensation ($USD1.66M) is above average for companies of similar size in the US market ($USD1.10M).
Compensation vs Earnings: BJ's compensation has increased whilst the company is unprofitable.
Experienced Management: ATHX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: ATHX's board of directors are considered experienced (7.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ATHX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19%.
Athersys, Inc.'s employee growth, exchange listings and data sources
- Name: Athersys, Inc.
- Ticker: ATHX
- Exchange: NasdaqCM
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$242.292m
- Shares outstanding: 235.24m
- Website: https://www.athersys.com
Number of Employees
- Athersys, Inc.
- 3201 Carnegie Avenue
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/26 23:02|
|End of Day Share Price||2021/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.